{
    "2019-01-09": [
        [
            {
                "time": "2023-10-15",
                "original_text": "Canopy Growth Moves to Key Resistance",
                "features": {
                    "keywords": [
                        "Canopy",
                        "Growth",
                        "Resistance"
                    ],
                    "sentiment_score": 0.7,
                    "policy_related": "false",
                    "investment_strategy": "false",
                    "sector_focus": [
                        "cannabis",
                        "healthcare"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "positive"
                }
            },
            {
                "time": "2023-10-15",
                "original_text": "Novartis' Crizanlizumab Gets Breakthrough Therapy Status",
                "features": {
                    "keywords": [
                        "Novartis",
                        "Crizanlizumab",
                        "Breakthrough",
                        "Therapy"
                    ],
                    "sentiment_score": 0.9,
                    "policy_related": "false",
                    "investment_strategy": "false",
                    "sector_focus": [
                        "pharmaceuticals",
                        "healthcare"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "positive"
                }
            }
        ]
    ]
}